These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36327625)

  • 61. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
    Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
    Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
    Saini KS; Punie K; Twelves C; Bortini S; de Azambuja E; Anderson S; Criscitiello C; Awada A; Loi S
    Expert Opin Biol Ther; 2021 Jul; 21(7):945-962. PubMed ID: 34043927
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
    Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
    Oncotarget; 2015 Sep; 6(26):22496-512. PubMed ID: 26101915
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors.
    Liao S; Wang B; Zeng R; Bao H; Chen X; Dixit R; Xing X
    Drug Dev Res; 2021 Dec; 82(8):1096-1110. PubMed ID: 34462935
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
    Zhu J; Wu W; Togashi Y; Taira Nihira N; Johmura Y; Zhu D; Nakanishi M; Miyoshi Y; Ohta T
    Breast Cancer; 2022 Nov; 29(6):1076-1087. PubMed ID: 35882754
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HER2-Low Breast Cancer: a New Subtype?
    Corti C; Giugliano F; Nicolò E; Tarantino P; Criscitiello C; Curigliano G
    Curr Treat Options Oncol; 2023 May; 24(5):468-478. PubMed ID: 36971965
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer.
    Epaillard N; Bassil J; Pistilli B
    Cancer Treat Rev; 2023 Sep; 119():102597. PubMed ID: 37454577
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
    Michaleas S; Moreno Oliver A; Mueller-Berghaus J; Sarac SB; van der Elst ME; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2022 Jun; 7(3):100497. PubMed ID: 35642987
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    Heist RS; Guarino MJ; Masters G; Purcell WT; Starodub AN; Horn L; Scheff RJ; Bardia A; Messersmith WA; Berlin J; Ocean AJ; Govindan SV; Maliakal P; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM; Camidge DR
    J Clin Oncol; 2017 Aug; 35(24):2790-2797. PubMed ID: 28548889
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
    Faltas B; Goldenberg DM; Ocean AJ; Govindan SV; Wilhelm F; Sharkey RM; Hajdenberg J; Hodes G; Nanus DM; Tagawa ST
    Clin Genitourin Cancer; 2016 Feb; 14(1):e75-9. PubMed ID: 26541586
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions.
    Morrison L; Okines A
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568617
    [TBL] [Abstract][Full Text] [Related]  

  • 73. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rise of Antibody-Drug Conjugates: The Present and Future.
    Shastry M; Gupta A; Chandarlapaty S; Young M; Powles T; Hamilton E
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390094. PubMed ID: 37229614
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer].
    Besnainou H; Cabel L
    Bull Cancer; 2024 Apr; 111(4):333-334. PubMed ID: 38458926
    [No Abstract]   [Full Text] [Related]  

  • 76. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].
    Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL
    Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer.
    Abelman RO; Keenan JC; Ryan PK; Spring LM; Bardia A
    Hematol Oncol Clin North Am; 2023 Feb; 37(1):151-167. PubMed ID: 36435607
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
    Lombardi P; Filetti M; Falcone R; Altamura V; Paroni Sterbini F; Bria E; Fabi A; Giannarelli D; Scambia G; Daniele G
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980630
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antibody-drug conjugates in HER2-positive breast cancer.
    Li L; Zhang D; Liu B; Lv D; Zhai J; Guan X; Yi Z; Ma F
    Chin Med J (Engl); 2021 Dec; 135(3):261-267. PubMed ID: 34935688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.